Physician profile
Michael Lemon
NPI 1801884689
$779.20
in general payments reported to CMS, 2019-2025
15 companies · $148 in 2025
The $148 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.22 · 2020: $31.57 · 2021: $174 · 2022: $131 · 2023: $150 · 2024: $121 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $419.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $113.94 | 2021-2024 | Qelbree, Qelbree |
| Glaxosmithkline, LLC. | $108.96 | 2021-2025 | Bexsero, Penmenvy |
| Ironshore Pharmaceuticals INC. | $101.87 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.42 | 2019-2022 | |
| Kaleo, INC. | $67.90 | 2021-2023 | Auvi-Q |
| Merck Sharp & Dohme LLC | $60.96 | 2021-2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Corium, LLC | $39.38 | 2022-2023 | Azstarys |
| Collegium Pharmaceutical, INC. | $36.68 | 2025 | Jornay Pm |
| Astrazeneca Pharmaceuticals Lp | $30.71 | 2024 | Flumist Quadrivalent |
| Genzyme Corporation | $30.52 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $23.31 | 2025 | Neffy |
| Ultragenyx Pharmaceutical INC. | $20.20 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.91 | 2025 | |
| Cipher Pharmaceuticals US LLC | $15.87 | 2025 | Spinosad, Natroba |
| Tris Pharma INC | $15.57 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lemon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.